US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bayer A.G.

10.45

+0.16001.55%

Volume:375.32K

Turnover:3.92M

Market Cap:41.07B

PE:-11.65

High:10.50

Open:10.39

Low:10.39

Close:10.29

52wk High:10.71

52wk Low:4.79

Shares:3.93B

Float Shares:3.93B

Volume Ratio:0.83

T/O Rate:0.01%

Dividend:0.03

Dividend Rate:0.30%

EPS(TTM):-0.8971

EPS(LYR):-0.6723

ROE:-0.57%

ROA:3.06%

PB:1.19

PE(LYR):-15.54

Loading ...

Overview Company News Filings

Bayer stock has its best day in 17 years after support from Trump's solicitor general

White House Backs Bayer's Bid for Supreme Court Review in Roundup Case

Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ

Bayer's stock is jumping on secondary stroke drug's trial success

Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment

Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study

Bayer announces FDA approval of Hyrnuo for non-small cell lung cancer

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell

Bayer price target raised to EUR 30.40 from EUR 26 at Berenberg

Bayer (BAYRY) Gets a Hold from Berenberg Bank

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks

Bayer Q3 Adj. EPS $0.17 Up From $0.07 YoY, Sales $11.295B Beat $10.930B Estimate

Bayer's Crop Science Unit Drives Strong Results -- Market Talk

Bayer's Litigation Costs in Focus -- Earnings Preview

Bayer names Judith Hartmann as CFO, succeeding Wolfgang Nickl

Bayer says FDA approves Lynkuet 60mg capsules for treatment of hot flashes

European Pharmaceutical Stocks Fall On New Trump Tariffs -- Market Talk

Bayer Canada, Mint Pharmaceuticals enter distribution partnership for ADALAT XL

Bayer, Merck & Co's Heart-Failure Drug Fails to Meet Target in Late-Stage Trial

Bayer Resolves PCB Exposure Lawsuits From Washington State School

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BAYRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":10.45,"timestamp":1766178000000,"preClose":10.29,"halted":0,"volume":375315,"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Market Closed","change":0.16,"latestTime":"12-19 16:00:00 EST Delay","open":10.39,"high":10.5,"low":10.39,"amount":3920061.1568,"amplitude":0.01069,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":10.29,"volumeRatio":0.8336987420714423},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"3.06%","roe":"-0.57%","lyrEps":-0.672343,"volumeRatio":0.8336987420714423,"shares":3929696328,"dividePrice":0.031,"high":10.5,"amplitude":0.01069,"preClose":10.29,"low":10.39,"week52Low":4.79,"pbRate":"1.19","psRate":"0.76","week52High":10.71,"institutionHeld":0.0018,"latestPrice":10.45,"eps":-0.897103,"divideRate":0.002967,"volume":375315,"delay":15,"ttmEps":-0.897103,"open":10.39,"prevYearClose":4.88,"prevWeekClose":10.68,"prevMonthClose":8.805,"prevQuarterClose":8.29,"fiveDayClose":10.68,"twentyDayClose":7.68,"sixtyDayClose":7.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1763096400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588803554","title":"Bayer stock has its best day in 17 years after support from Trump's solicitor general","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588803554?lang=en_us&edition=fundamental","pubTime":"2025-12-02 16:52","pubTimestamp":1764665520,"startTime":"0","endTime":"0","summary":"A file photo taken on September 1, 2019 shows Roundup weedkiller on sale that is the subject of thousands of lawsuits in the U.S. Bayer stock rose on Tuesday after the U.S. solicitor general backed the company in an amicus brief to the Supreme Court.Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company's bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.Analysts said the move will support the German company's attempts to resolve litigation around what's called glyphosate by the end of 2026. Solicitor General D. John Sauer on Monday said the Environmental Protection Agency repeatedly has stated that glyphosate  is not likely to be carcinogenic in humans and that the agency has repeatedly approved Roundup labels without cancer warnings.Bayer welcomed the support in the lawsuit, Monsanto Co. vs. Durnell, and the issue of whether a federal insecticide rule preempts state law. Bayer said \"tens of thousan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2588700087","title":"White House Backs Bayer's Bid for Supreme Court Review in Roundup Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2588700087","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588700087?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:27","pubTimestamp":1764660420,"startTime":"0","endTime":"0","summary":"Bayer said it welcomed the U.S. Solicitor General's support for a Supreme Court review of a case that could curtail longrunning litigation regarding its Roundup pesticide.The German life-sciences company said the government's support would be significant as the Court weighs its petition, arguing that federal pesticide law preempts state-level failure-to-warn claims. This could limit tens of thousands of lawsuits alleging that the company's Roundup weed-killer causes cancer.Solicitor General D. John Sauer in a brief said that \"[the Environmental Protection Agency] has repeatedly determined that glyphosate is not likely to be carcinogenic in humans, and the agency has repeatedly approved Roundup labels that did not contain cancer warnings.\". Bayer previously stated that it aims to significantly contain Roundup litigation by the end of 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"White House Backs Bayer's Bid for Supreme Court Review in Roundup Case","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2585685064","title":"Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585685064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585685064?lang=en_us&edition=fundamental","pubTime":"2025-11-24 17:50","pubTimestamp":1763977800,"startTime":"0","endTime":"0","summary":"Alibaba : The Chinese e-commerce leader said its Qwen artificial-intelligence app drew more than 10 million downloads in the first week after a relaunch. Shares jumped 4.7% in Hong Kong.Tyson Foods : America's largest meat supplier plans to close a major beef-processing plant, as a cattle shortage squeezes the industry.Anglo American : Following fresh talks, BHP  said it wouldn't pursue a takeover of its London-listed rival, clearing the way for Anglo to close a merger with Teck Resources .Comcast : Universal Pictures movie \"Wicked: For Good\" opened in U.S. and Canadian theaters with ticket sales worth an estimated $150 million, one of the biggest domestic debuts of 2025. Comcast owns Universal.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMCSA","LU2720916845.USD","LU1221951046.USD","IE00BZ199S13.USD","LU0594300419.USD","LU2125910849.SGD","IE00BQXX3D17.EUR","HBBD.SI","LU0648948544.HKD","LU0348788117.USD","LU2764263203.CNY","BK4007","LU1303224171.USD","LU2326559502.SGD","LU2362541513.USD","LU0345774631.USD","LU0499858438.USD","LU2125154935.USD","LU0203201768.USD","LU2764263039.SGD","09988","BK1142","LU2039709279.SGD","BK4588","LU1037948541.HKD","BAYRY","LU1044874839.SGD","LU0326950275.SGD","IE00BMPRXR70.SGD","TSLA","LU0345781412.USD","LU1069344957.HKD","TSN","AKZOY","LU2191332357.HKD","LU0359202008.SGD","LU0039217434.USD","LU0370786039.SGD","BABA","USJW.SI","89988","TSYW.SI","ALBmain","LU0203202063.USD","TSLL","IE00B3S45H60.SGD","TECK","BK4077"],"gpt_icon":1},{"id":"2585468890","title":"Bayer's stock is jumping on secondary stroke drug's trial success","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468890","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585468890?lang=en_us&edition=fundamental","pubTime":"2025-11-24 17:47","pubTimestamp":1763977620,"startTime":"0","endTime":"0","summary":"Bayer shares rose on Monday after the company said a late-stage trial of a stroke drug met its goals.Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.Bayer didn't give too much away: on Sunday the company said a Phase III trial with 12,300 patients of an oral drug called Asundexian significantly reduced the risk of a secondary stroke, and that there also was no increase in the risk of major bleeding.It will present detailed results at an upcoming scientific congress.Bayer says that of the 12 million people who suffer a stroke each year, 20% to 30% will be a recurrent stroke, and that one in five stroke survivors have another one in five years. The drug works by inhibiting what's called Factor XIa, which can lead to blood clotting.\"This is a material de-risking event for Bayer's pipeline, validating FXIa inhibition as a differentiated anticoagulation approach,\" said analysts at Jefferies.Bayer shares  jumped 11%, add","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2585445503","title":"Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2585445503","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585445503?lang=en_us&edition=fundamental","pubTime":"2025-11-24 14:46","pubTimestamp":1763966760,"startTime":"0","endTime":"0","summary":"Bayer said it had positive results in late-stage clinical trials for a drug preventing stroke, after a previous study with the same drug failed to reduce blood-clot formation.The German pharmaceutical company said Sunday that the once-daily 50mg asundexian medication, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study. It did so without causing major bleeding, a side effect of other blood thinning medications, Bayer said.The drug blocks Factor XIa, a protein that contributes to blood clotting, Bayer said.Bayer said it met the primary objective of the Phase 3 Oceanic-Stroke trial.It halted a Phase 3 clinical trial last year testing the effectiveness of the experimental drug for stroke and systemic embolism prevention. At the time, the trial's failure dealt a blow to Bayer's pharmaceutical division, as it was expected to bring the division back to growth.The company said it would work with global health authorities as it prepares marketing au","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2585438825","title":"Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585438825","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585438825?lang=en_us&edition=fundamental","pubTime":"2025-11-24 05:30","pubTimestamp":1763933413,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayers-asundexian-met-primary-efficacy-safety-endpoints-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayers-asundexian-met-primary-efficacy-safety-endpoints-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY","BK4134","III"],"gpt_icon":0},{"id":"2584133134","title":"Bayer announces FDA approval of Hyrnuo for non-small cell lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584133134","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584133134?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:17","pubTimestamp":1763644643,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that the FDA has approved Hyrnuo, an oral, reversible, tyrosine kinase inhibitor for the treatment of adult patients with l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-announces-fda-approval-of-hyrnuo-for-non-small-cell-lung-cancer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-announces-fda-approval-of-hyrnuo-for-non-small-cell-lung-cancer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2584978778","title":"FDA grants accelerated approval to sevabertinib for non-squamous non-small cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2584978778","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584978778?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:55","pubTimestamp":1763582133,"startTime":"0","endTime":"0","summary":"On November 19, 2025, the Food and Drug Administration granted accelerated approval to Bayer’s (BAYRY) sevabertinib, a kinase inhibitor, for adults...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-grants-accelerated-approval-to-sevabertinib-for-non-squamous-non-small-cell-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-grants-accelerated-approval-to-sevabertinib-for-non-squamous-non-small-cell-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2583902685","title":"Bayer price target raised to EUR 30.40 from EUR 26 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2583902685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583902685?lang=en_us&edition=fundamental","pubTime":"2025-11-15 01:45","pubTimestamp":1763142334,"startTime":"0","endTime":"0","summary":"Berenberg analyst Sebastian Bray raised the firm’s price target on Bayer (BAYRY) to EUR 30.40 from EUR 26 and keeps a Hold rating on the shares. Pu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-30-40-from-eur-26-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-30-40-from-eur-26-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2583852418","title":"Bayer (BAYRY) Gets a Hold from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2583852418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583852418?lang=en_us&edition=fundamental","pubTime":"2025-11-14 14:36","pubTimestamp":1763102184,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Berenberg Bank maintained a Hold rating on Bayer, with a price target of $8.80. The company’s shares closed ye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bayer-bayry-gets-a-hold-from-berenberg-bank-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bayer-bayry-gets-a-hold-from-berenberg-bank-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2583011083","title":"Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2583011083","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583011083?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:34","pubTimestamp":1762972491,"startTime":"0","endTime":"0","summary":"Bayer&#39;s Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company&#39;s upgraded 2025 guidance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48814095/agricultural-conglomerate-bayer-confident-in-long-term-outlook-despite-litigation-risks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY","BAYZF"],"gpt_icon":0},{"id":"2582764703","title":"Bayer Q3 Adj. EPS $0.17 Up From $0.07 YoY, Sales $11.295B Beat $10.930B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582764703","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582764703?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:40","pubTimestamp":1762951204,"startTime":"0","endTime":"0","summary":"Bayer (OTC:BAYRY) reported quarterly earnings of $0.17 per share. This is a 142.86 percent increase over earnings of $0.07 per share from the same period last year.  The company reported quarterly sales of $11.295","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799804/bayer-q3-adj-eps-0-17-up-from-0-07-yoy-sales-11-295b-beat-10-930b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2582320674","title":"Bayer's Crop Science Unit Drives Strong Results -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582320674","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582320674?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:15","pubTimestamp":1762946100,"startTime":"0","endTime":"0","summary":"1115 GMT - Strong results for Bayer's crop science segment helped offset a guidance cut for its consumer-health unit, JPMorgan analysts write in a note. A decline in the costs of goods sold, improved spending efficiencies and lower-than-expected reconciliation costs also supported the generally strong third quarter, the bank says. The German healthcare-and-agriculture company's significant exposure to challenging markets in the U.S. and China undercut consumer-health performance and contributed to the weaker outlook, Chief Financial Officer Wolfgang Nickl said in a call following the results. Shares rise 4.5% to trade at 28.67 euros. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2582836578","title":"Bayer's Litigation Costs in Focus -- Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2582836578","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582836578?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:06","pubTimestamp":1762862760,"startTime":"0","endTime":"0","summary":"Bayer is scheduled to report results for the third quarter on Wednesday. Here is what you need to know.SALES FORECAST: The German pharmaceutical and agricultural group is expected to post third-quarter sales of 9.69 billion euros  according to median consensus estimates provided by Vara Research. Bayer reported sales of 9.97 billion euros for the same period last year.PROFIT FORECAST: Bayer is expected to post a third-quarter net loss of 413 million euros, narrowing from a net loss of 4.18 billion euros in the same period last year, when the company booked impairment losses at its crop-science business. The group is forecast to post earnings before interest, taxes, depreciation and amortization before special items--a key company metric--of 1.27 billion euros. For the third quarter of last year, Bayer made Ebitda before special items of 1.25 billion euros.Shares in Bayer rose 11% during the third quarter and were up 37% since the start of the year through Monday's close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","IE00BZ1G4Q59.USD","LU1244550577.SGD","LU0106831901.USD","LU0106261372.USD","LU1074936037.SGD","BK4585","LU0557290698.USD","LU0795875169.SGD","BK4504","LU0098860793.USD","LU0158827781.USD","LU2028103732.USD","BK4534","LU0267386448.USD","LU1363072403.SGD","BK4588","LU0006306889.USD","LU0314104364.USD","LU1720051017.SGD","LU1989772923.USD","LU2347655156.SGD","LU0971096721.USD","BK4127","LU0882574139.USD","LU0795875086.SGD","LU2089284900.SGD","LU1989772840.SGD","LU2111349929.HKD","BK4581","LU1732799900.SGD","LU0320765646.SGD","LU0912757837.SGD","LU1162221912.USD","BK4516","BAYRY","LU0158827948.USD","BK4007","LU1720051108.HKD","LU2133065610.SGD","LU1548497426.USD","LU1668664300.SGD","IE00BKVL7J92.USD","LU0225283273.USD","LU2089283258.USD","LU2271345857.HKD","LU2023251221.USD","LU1244550221.USD","LU1244550494.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2581013684","title":"Bayer names Judith Hartmann as CFO, succeeding Wolfgang Nickl","url":"https://stock-news.laohu8.com/highlight/detail?id=2581013684","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581013684?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:50","pubTimestamp":1762447845,"startTime":"0","endTime":"0","summary":"The Supervisory Board of Bayer (BAYRY) AG has appointed Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will suc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-names-judith-hartmann-as-cfo-succeeding-wolfgang-nickl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-names-judith-hartmann-as-cfo-succeeding-wolfgang-nickl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2578413735","title":"Bayer says FDA approves Lynkuet 60mg capsules for treatment of hot flashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2578413735","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578413735?lang=en_us&edition=fundamental","pubTime":"2025-10-25 01:30","pubTimestamp":1761327018,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced today the U.S. Food and Drug Administration has approved Lynkuet 60mg capsules, the first and only dual neurokinin targeted...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-says-fda-approves-lynkuet-60mg-capsules-for-treatment-of-hot-flashes-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-says-fda-approves-lynkuet-60mg-capsules-for-treatment-of-hot-flashes-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2570077446","title":"European Pharmaceutical Stocks Fall On New Trump Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2570077446","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570077446?lang=en_us&edition=fundamental","pubTime":"2025-09-26 15:38","pubTimestamp":1758872280,"startTime":"0","endTime":"0","summary":"0737 GMT - European pharmaceutical stocks fell in early trade after President Trump announced 100% tariffs on those companies that aren't building plants in the U.S. Swiss skincare company Galderma was the biggest faller, losing 3.55%, while Novo Nordisk shares are down 1.3%. AstraZeneca, Roche and Bayer shares were all down 0.2%. Tariffs are expected to start from Oct. 1.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4532","NVO","BK4007","AZN","BAYRY","BK4585","LU2462157665.USD","BK4588","LU0889565916.HKD","LU1829250122.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU2417539215.USD","LU2236285917.USD","BK4599","LU2456880835.USD","LU0320765992.SGD","RHHBY","03165","BK4568","LU0109394709.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2570165750","title":"Bayer Canada, Mint Pharmaceuticals enter distribution partnership for ADALAT XL","url":"https://stock-news.laohu8.com/highlight/detail?id=2570165750","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570165750?lang=en_us&edition=fundamental","pubTime":"2025-09-25 22:05","pubTimestamp":1758809123,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) Canada announced a new partnership with Mint Pharmaceuticals for the distribution of ADALAT XL 30 mg tablets in Canada. This strategi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-canada-mint-pharmaceuticals-enter-distribution-partnership-for-adalat-xl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-canada-mint-pharmaceuticals-enter-distribution-partnership-for-adalat-xl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2564895210","title":"Bayer, Merck & Co's Heart-Failure Drug Fails to Meet Target in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2564895210","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564895210?lang=en_us&edition=fundamental","pubTime":"2025-09-01 13:55","pubTimestamp":1756706100,"startTime":"0","endTime":"0","summary":"Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study.The German conglomerate on Monday said vericiguat in the phase 3 Victor trial, which compares the efficacy of the drug to placebo in patients with heart failure with reduced ejection fraction, didn't reach statistical significance for its primary endpoint.In the EU, vericiguat is used  for the treatment of symptomatic chronic heart failure in adult patients, Bayer said.The overall safety profile of vericiguat in the trial was consistent with previous clinical trials, it added.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU1066051225.USD","SGXZ57979304.SGD","LU1093756325.SGD","LU1934455863.HKD","LU0265550946.USD","SG9999001176.SGD","SG9999001176.USD","LU2112291526.USD","LU1057294990.SGD","BK4516","LU0965509010.AUD","SG9999014559.SGD","SG9999014567.USD","LU0098860793.USD","IE00BN8TJ469.HKD","SSI","LU1162221912.USD","LU2089984988.USD","LU1571399168.USD","LU1035773651.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0965509101.SGD","LU2468319806.SGD","LU0289739699.SGD","SG9999001440.SGD","LU0208291251.USD","LU1929549753.HKD","BAYRY","LU0211331839.USD","LU1430594728.SGD","SG9999015358.SGD","SG9999014575.USD","LU1585245621.USD","MRK","IE00B4R5TH58.HKD","LU0234572021.USD","LU1699723380.USD","SG9999002232.USD","SG9999014542.SGD","LU0266013472.USD","LU1069347547.HKD","LU2461242641.AUD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2023250504.SGD","SG9999013999.USD","LU0985320562.USD","BK4533"],"gpt_icon":0},{"id":"2560900143","title":"Bayer Resolves PCB Exposure Lawsuits From Washington State School","url":"https://stock-news.laohu8.com/highlight/detail?id=2560900143","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560900143?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:55","pubTimestamp":1755521700,"startTime":"0","endTime":"0","summary":"Bayer's Monsanto agreed to resolve lawsuits representing more than 200 plaintiffs who allege they were sickened by exposure to polychlorinated biphenyls at Sky Valley Education Center in Washington state.The agreement doesn't include adverse jury decisions in nine prior cases involving 49 plaintiffs, which the company is continuing to appeal.The terms are confidential and still subject to approval of final settlement agreements. The company said the costs of the agreements would be covered by the PCB litigation provision it established in the second quarter, which it previously said would be worth EUR 530 million.Bayer has been the target of a string of lawsuits by students, employees and parents at the Monroe, Wash. school who say they developed cancer, thyroid problems and neurological issues as a result of exposure to PCBs made by Monsanto, which Bayer bought in 2018, in the school's light fixtures.In January, a jury ordered the company to pay $100 million to four plaintiffs, while ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4007","BAYRY","PCB","IE00B64PRP62.GBP","BK4588","IE0034235188.USD","IE00BGHQF748.EUR","LU1883839398.USD","LU1894683348.USD","STT","LU0061475181.USD","WASH","BK4585","IE00B3QW5Z07.USD","BK4135","LU1894683264.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}